首页> 外文期刊>Microbiome >Discovery of a novel integron-borne aminoglycoside resistance gene present in clinical pathogens by screening environmental bacterial communities
【24h】

Discovery of a novel integron-borne aminoglycoside resistance gene present in clinical pathogens by screening environmental bacterial communities

机译:通过筛选环境细菌社区发现临床病原体中的一种新型整合氨基糖苷类抗性基因

获取原文
           

摘要

BACKGROUND:New antibiotic resistance determinants are generally discovered too late, long after they have irreversibly emerged in pathogens and spread widely. Early discovery of resistance genes, before or soon after their transfer to pathogens could allow more effective measures to monitor and reduce spread, and facilitate genetics-based diagnostics.RESULTS:We modified a functional metagenomics approach followed by in silico filtering of known resistance genes to discover novel, mobilised resistance genes in class 1 integrons in wastewater-impacted environments. We identified an integron-borne gene cassette encoding a protein that conveys high-level resistance against aminoglycosides with a garosamine moiety when expressed in E. coli. The gene is named gar (garosamine-specific aminoglycoside resistance) after its specificity. It contains none of the functional domains of known aminoglycoside modifying enzymes, but bears characteristics of a kinase. By searching public databases, we found that the gene occurs in three sequenced, multi-resistant clinical isolates (two Pseudomonas aeruginosa and one Luteimonas sp.) from Italy and China, respectively, as well as in two food-borne Salmonella enterica isolates from the USA. In all cases, gar has escaped discovery until now.CONCLUSION:To the best of our knowledge, this is the first time a novel resistance gene, present in clinical isolates, has been discovered by exploring the environmental microbiome. The gar gene has spread horizontally to different species on at least three continents, further limiting treatment options for bacterial infections. Its specificity to garosamine-containing aminoglycosides may reduce the usefulness of the newest semisynthetic aminoglycoside plazomicin, which is designed to avoid common aminoglycoside resistance mechanisms. Since the gene appears to be not yet common in the clinics, the data presented here enables early surveillance and maybe even mitigation of its spread.
机译:背景:新的抗生素抗性决定簇通常为时已晚,在病原体中不可逆转地出现并广泛蔓延。在转移到病原体之前或之后的早期发现抗性基因可以允许更有效的措施监测和减少蔓延,并促进基于遗传学的诊断。结果:我们修改了一种功能性的聚焦方法,然后在已知的抗性基因的硅滤波中进行了修改在废水冲击环境中探索1级整合店中的新型动员的抗性基因。我们鉴定了编码一种蛋白质的整合基因盒,其在大肠杆菌中表达时用甘蔗胺部分对甘蓝醛部分传达对氨基糖苷的高水平阻力。在其特异性后,基因被命名为GAR(甘蔗胺特异性氨基糖苷抵抗力)。它不含已知的氨基糖苷类改性酶的功能域,但是具有激酶的特征。通过搜索公共数据库,我们发现该基因分别发生在三种测序,多种抗性临床分离株(两种Pseudomonas Aeruginosa和一只Quatimonas SP。),分别来自意大利和中国,以及两种食物传播的沙门氏菌肠道分离物美国。在所有情况下,GAR才逃脱了发现。结论:据我们所知,这是首次通过探索环境微生物组的临床分离株中存在的新抗性基因。 GAR基因在至少三大洲水平分布到不同物种,进一步限制了细菌感染的治疗方案。其对含甘蔗胺的氨基糖苷的特异性可以减少最新的半合成氨基糖苷丙唑啉的有用性,其旨在避免常见的氨基苷抗性机制。由于基因在诊所似乎尚不常见,因此这里提出的数据能够提前监视,甚至可能减轻其传播。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号